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Monocyte-derived dendritic cells (DCs) from adult T cell leukemia are impaired in taking up exogenous antigens. To
overcome this impairment, we fused unpulsed DCs to human T-lymphotropic virus type I (HTLV-I)-infected CD4 T cells
(fusion DC-T cells). The efficiency of fusion was 50% and the fusion cells expressed higher HLA-ABC and CD86 Ags than
HTLV-I-infected DCs. The fusion DC-T cells stimulated autologous CD4 and CD8 T cells, but DCs fused to itself or
PHA-blasts did not stimulate any subsets. The functionally highest fusion DC-T cells was obtained when a DC and
HTLV-I-infected T cells were fused at a ratio of 3:1. Expression of HTLV-Igag Ag on CD4 T cells was up-regulated when
infected in the presence of 8-azaguanine, and these fusion DC-T cells were quite efficient in induction of higher CD8 T cell
response. The results suggest that fusion DC-T cells produce functionally competent Ag-presenting cells and may be a likelyINTRODUCTION
Human T-lymphotropic virus type I (HTLV-I) is an etio-
logical agent of adult T cell leukemia (ATL) and trans-
mission of the virus occurs through breast milk in the
newborn period (Takatsuki et al., 1977; Uchiyama et al.,
1977; Hino et al., 1985; Nakano et al., 1986; Kusuhara et
al., 1987). After infection, most individuals do not show
monoclonal expansion of HTLV-I-infected CD4 T cells
for more than 40 years (Uchiyama, 1997). During this
asymptomatic carrier state, cytotoxic T lymphocytes of
CD8 phenotype seem to work chiefly in inhibiting out-
growth of leukemic T cells (Kannagi et al., 1983, 1991;
Jacobson et al., 1990). Activation of CD8 T cells abso-
lutely requires Ag-presenting cells (APCs). Once the im-
mune system has been impaired by unknown mecha-
nisms, HTLV-I-infected individuals are speculated to al-
low monoclonal expansion of leukemic T cells, which
further leads the host into an immunocompromised state
(Hollsberg and Hafler, 1993; Funai et al., 1996). Therefore,
ATL manifestation is highly associated with host immu-
nological states. In fact, ATL patients show low T cells
responsiveness to Ags in general, and reactivation of
uninfected CD4 T cells and CD8 T cells is not feasibly
induced in vitro (Kannagi et al., 1983, 1991). Based on
these observations, the most powerful APC should be
1 To whom correspondence and reprint requests should be addressed
at Department of Microbiology, Leprosy Research Center, National Insti-13enrolled in the activation of these T cells. In this respect,
dendritic cells (DCs) could be the most potent APCs,
because they can stimulate both naive and memory
phenotypes of CD4 and CD8 T cells (Inaba et al., 1987,
1990).
In a previous article, we demonstrated that monocyte-
derived DCs were susceptible to HTLV-I infection in vitro
and in vivo (Makino et al., 1999) and that the DCs differ-
entiated from peripheral monocytes in ATL patients were
impaired in taking up exogenous Ags and stimulating
allogeneic T cells (Makino et al., 2000). Furthermore,
peripheral CD4 T cells in ATL patients could not ex-
press CD40 ligand molecules, which play a central role
in the differentiation and terminal activation of DCs to
mature DCs (Makino et al., 2001). As far as we know, no
efficient or reliable immunotherapeutic tools against ATL
have been established, and their urgent development is
desired. The most effective tools for immunotherapy
against ATL are activated CD8 T cells, so that the
functionally competent DCs should be activated. How-
ever, the previous article has indicated that the prepara-
tion of functionally competent DCs from peripheral
monocytes in ATL patients is difficult (Makino et al.,
2001).
Several immunotherapeutic tools using DCs have re-
cently been developed against malignant tumor cells,
including artificial induction of tumor-associated Ags to
DCs (Mayordomo et al., 1995; Celluzzi et al., 1996; Hsu et
al., 1996; Paglia et al., 1996; Nestle et al., 1998; Nieda et
al., 1998), tumor Ag-specific gene transfection to DCscandidate for immunotherapeutic use.
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1997a; Ribas et al., 1997; Song et al., 1997a,b; Specht et
al., 1997), and fusion of DCs and tumor cells (Gong et al.,
1997b, 1998, 2000a,b; Lespagnard et al., 1998; Wang et
al., 1998; Kugler et al., 2000). Among them, the fusion of
DCs with tumor cells seems quite useful in vivo as well
as in vitro in the induction of MHC class I pathway-
mediated CD8 T cell immunity (Gong et al., 2000a).
Therefore, we examined the effects of fusion of mature
DCs from healthy donors and autologous HTLV-I-infected
T cells on the APC function for the development of a new
immunotherapeutic tool against ATL.
RESULTS
Phenotypic analysis of fusion DC-T cells
Mature DCs, unpulsed with any specific antigen (Ag),
were fused with autologous HTLV-I-infected CD4 T cells
and the fusion DC-T cells were analyzed for the expres-
sion of surface molecules. Since immature DCs could be
infected with cell-free HTLV-I as reported previously
(Makino et al., 1999), DCs infected with the cell-free
virions and the mature unpulsed DCs were used as
control cells (Fig. 1). CD2 molecule is a T cell marker and
is not expressed on DCs. We used this molecule to
monitor the fusion efficiency. Neither DCs unpulsed nor
infected with cell-free HTLV-I expressed CD2 Ag; how-
ever, around 50% of fusion DC-T cells were CD2 Ag-
positive when DC population (50–70% of the total popu-
lation) was analyzed and these CD2-positive cells were
considered to be fused. Similar expression of CD3 Ag
was observed (not shown). The viability of fusion DC-T
cells was around 60–70% among DC population. All of
these cells expressed APC-related molecules (MHC,
CD86, CD80, CD40, and CD54 Ags); however, the expres-
sion levels of MHC class I and CD86 Ags were signifi-
cantly higher on fusion DC-T cells than on HTLV-I-in-
fected DCs. There were no significant differences among
fusion DC-T cells, virus-infected DCs, and unpulsed DCs
in the expression of MHC class II, CD80, CD40, and
CD54 molecules. Furthermore, fusion DC-T cells faintly
expressed HTLV-Igag Ags on the surface (not shown).
Ag-presentation function of fusion DC-T cells
An APC function of Ag-unpulsed mature DCs-autolo-
gous HTLV-I-infected CD4 T cells fusion was examined
using autologous mixed lymphocyte reactions (MLRs)
(Fig. 2). All of the mature DCs, HTLV-I-infected CD4 T
cells, and responder T cells were obtained from the
same donor. In the process of preparing fusion DC-T
cells, there is a possibility of DCs–DCs fusion and HTLV-
I-infected T cells–HTLV-I-infected T cells fusion occur-
ring. Therefore, the APC function of fusion DC-T cells
was examined in reference to that of DCs–DCs fusion
(unpulsed with any Ag) and the T cells–T cells fusion.
While these control fusions minimally stimulated autolo-
gous T cells, fusion DC-T cells induced significant T cell
proliferation. Furthermore, when autologous phytohe-
FIG. 1. Expression of various molecules on DCs and fusion of DCs and HTLV-I-infected T cells. Immature DCs were differentiated from monocytes
obtained from healthy individuals and were unpulsed or infected with HTLV-I by using cell-free virions. Fusion DC-T cells were prepared using
LPS-matured DCs and HTLV-I-infected CD4 T cells. LPS treatment did not induce apparent cell death of DCs. —, control IgG; —, indicated mAb. The
number in each panel represents the mean fluorescence intensity. Assays were done in triplicate and the mean  standard deviation is shown. A
representative of three independent experiments is shown. aP  0.005. bP  0.05.
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magglutinin-P (PHA) blasts were used as a fusion part-
ner of DCs unpulsed with any Ags, instead of HTLV-I-
infected CD4 T cells, the DC-PHA blasts fusion did not
stimulate autologous T cells. Unfused HTLV-I-infected T
cells and the mixture of the T cells and DCs also did not
stimulate them (not shown). These results suggest that
HTLV-I-infected CD4 T cells are required as a fusion
partner for the induction of vigorous T cell proliferation.
In general, CD4 T cells are immortalized in vitro by
infection with HTLV-I and can be maintained in the pres-
ence of interleukin (IL)-2. We determined time-dependent
changes of APC function of fusion DC-T cells after fusion
(Fig. 3). The maximum proliferative responses of autolo-
gous CD4 and CD8 T cells were induced after 24 h of
fusion and were rapidly reduced thereafter. The viability
of the fusion DC-T cells was also rapidly reduced in a
time-dependent manner (not shown) and, at all time
points examined, CD4 T cells were predominantly stim-
ulated. Furthermore, we determined the optimal condi-
tions to obtain fully functional fusion DC-T cells. To this
end, we fused DCs with various numbers of HTLV-I-
infected CD4 T cells (Fig. 4). The APC function of these
cells showed a “bell-shaped phenomenon” and the high-
est APC function was achieved at a DC:T cell ratio of 3:1.
Both fusion DC-T cells prepared under this condition and
virus-infected DCs stimulated autologous CD4 and
CD8 T cells; however, the former induced a significantly
higher proliferation of T cells (Fig. 5).
Relationship between HTLV-I Ag expression on
HTLV-I-infected CD4 T cells and APC function
of fusion DC-T cells
It has been reported that metabolic antagonists up-
regulate the surface expression of tumor-associated Ags
(Weber et al., 1994). We applied this system to HTLV-I-
infection using 8-azaguanine (8Az) as a model com-
pound, because HTLV-I is a causative agent of ATL.
CD4 T cells obtained from healthy donors were infected
with HTLV-I in vitro in the presence or absence of 8Az.
Seven days after infection, the expression of HTLV-Igag
Ag was determined (Fig. 6). A significantly higher HTLV-
Igag Ag was expressed on HTLV-I-infected T cells in-
fected in the presence of 8Az than on those prepared in
FIG. 3. Time-dependent change of the APC function of fusion DC-T
cells. Mature DCs were fused with HTLV-I-infected T cells. After 1, 3,
and 5 days, fusion DC-T cells were cocultured with autologous CD4
(E) or CD8 (F) T cells (1  105/well) at a DC:T cell ratio of 1:20. A
representative of three independent experiments is shown. Each ex-
periment was performed in triplicate and the mean  standard devia-
tion is shown.
FIG. 4. Assessment of APC function of fusion DC-T cells. Mature DCs
were fused with autologous HTLV-I-infected CD4 T cells at the indi-
cated DC:CD4 T cell ratios. After 24 h, the fusion DC-T cells were
cocultured with autologous CD4 (o) and CD8 () T cells (1 
105/well) for 4 days at a fusion:T cells ratio of 1:20. A representative of
three independent experiments is shown. Each experiment was per-
formed in triplicate and the mean  standard deviation is shown.
FIG. 2. An APC function of fusion DC-T cells. Fusions of mature DCs
and HTLV-I-infected CD4 T cells (Fusion DC-T cells), mature Ag-
unpulsed DCs, and the mature DCs (DCs/DCs fusion), CD4 T cells
and CD4 T cells (T cell/T cell fusion) and mature DCs and autologous
PHA blasts (DCs/PHA blasts fusion) were prepared. These fusions
were cocultured with autologous unseparated PBMCs (1  105/well)
for 4 days at a fusion:PBMC ratio of 1:20. A representative of three
independent experiments is shown. Each experiment was performed in
triplicate and the mean  standard deviation is shown.
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the absence of 8Az. We determined the influence of 8Az
on the APC function of fusion DC-T cells (Fig. 7). Although
HTLV-I-infected cells produced either with or without 8Az
did induce proliferative responses of CD4 and CD8 T
cells, there was a significant difference in the CD8 T
cells response. A significantly higher proliferation was
induced when CD8 T cells were infected in the pres-
ence of 8Az, while no significant difference was ob-
served in the CD4 T cell response.
DISCUSSION
During an asymptomatic carrier state, CD8 CTL is
thought to play an important role in the suppression of
leukemic T cell expansion (Kannagi et al., 1983, 1991;
Jacobson et al., 1990). For activation of CD8 T cells, a
potent APC is absolutely required. However, DCs ob-
tained from ATL patients were impaired in taking up
exogenous Ags in vitro (Makino et al., 2000). To obtain an
immunological tool for overcoming this impairment, an
attempt was made to prepare functionally competent DC.
For this purpose, we made fusion cells between mature
Ag-unpulsed DCs and HTLV-I-infected CD4 T cells (fu-
sion DC-T cells). The latter were used as antigens, be-
cause both HTLV-I-infected DCs and HTLV-I-infected
CD4 T cells stimulated autologous CD4 and CD8 T
cells in an antigen-specific fashion as previously re-
ported (Takamoto et al., 1997; Makino et al., 1999); there-
fore, the fusion DC-T cells are expected to stimulate
autologous uninfected T cells in an Ag-specific manner.
The APC function of fusion DC-T cells was assessed by
their ability to stimulate T cell proliferation. Recently,
fusion cells of DCs and tumor cells have been used as
an immunotherapeutic tool in a field of cancer (Gong et
FIG. 5. Comparison of DC-T cells and HTLV-I-infected DCs. Immature
DCs were differentiated from healthy donor monocytes and were in-
fected with HTLV-I using cell-free virions. Fusion DC-T cells were
prepared by LPS-matured DCs and HTLV-I-infected CD4 T cells. The
fusion DC-T cells and virus-infected DCs were cocultured with autolo-
gous CD4 (o) and CD8 () T cells (1  105/well) for 4 days at a
fusion:T cells ratio of 1:20. A representative of three independent
experiments is shown. Each experiment was performed in triplicate
and the mean  standard deviation is shown. aP  0.01.
FIG. 6. Expression of HTLV-Igag Ag on HTLV-I-infected CD4 T cells.
CD4 T cells were obtained from healthy donors and were infected with
HTLV-I using MT-2 cells as a viral source in the presence or absence of
8Az. Seven days after infection, the expression of HTLV-Igag Ag on T cells
was determined by using FACScan. PHA blasts were used as a negative
control. The number in each panel represents the mean fluorescence
intensity. A representative of three independent experiments is shown.
Each experiment was performed in triplicate and the mean  standard
deviation is shown. aP  0.05.
FIG. 7. Effect of 8Az treatment on HTLV-I-infected CD4 T cells.
HTLV-I-infected T cells were produced in the absence () or presence
() of 8Az and were fused with autologous mature DCs. The fusion
DC-T cells were cocultured with autologous CD4 (o) and CD8 () T
cells (1  105/well) at stimulator:CD4 T cell ratio of 1:40 and at
stimulator:CD8 T cell ratio of 1:10. A representative of three indepen-
dent experiments is shown. Each experiment was performed in tripli-
cate and the mean  standard deviation is shown. aP  0.05.
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al., 1997b, 1998, 2000a,b; Lespagnard et al., 1998; Wang
et al., 1998; Kugler et al., 2000), and they are found to be
especially potent in the induction of MHC class I path-
way-mediated polyclonal CD8 T cell activation, al-
though both MHC class I and II pathways are activated
(Wang et al., 1998; Gong et al., 2000a,b). Furthermore, the
fusion cells induce immunity against both known and
unidentified multiple antigens and effectively elicits T cell
immunity against poorly immunogenic Ags (Gong et al.,
1997b; Wang et al., 1998). Most ATL cells do not express
HTLV-I Ags and are considered to be poor immunogenic
cancer cells. Therefore, the fusion cells seem to be
attractive for the induction of T cell immunity against ATL
cells. In our system using HTLV-I-infected CD4 T cells
as a fusion partner of DCs, fusion DC-T cells vigorously
stimulated both CD4 and CD8 T cell subsets. The
extent of stimulation was significantly higher than that
induced by HTLV-I-infected DCs. Concerning the CD8 T
cell response, the fusion DC-T cells expressed higher
levels of MHC class I and CD86 Ags than HTLV-I-infected
DCs (Fig. 1). These results indicate that fusion DC-T cells
might be a potent inducer of higher CD8 T cells re-
sponse against HTLV-I Ags. In the case of CD4 T cell
response, there was no significant difference in the ex-
pression of MHC class II Ags between fusion DC-T cells
and virus-infected DCs. Therefore, the higher CD4 T cell
response might be due to the higher expression of CD86
Ags on fusion DC-T cells.
Concerning the higher proliferative response induc-
tion, another explanation might be possible. We have
reported previously that, when cell-free HTLV-I virion was
used as a viral source, around 10–30% of DCs were
infected as far as examined by the surface expression of
viral Ags (Makino et al., 2000). In the present article, the
fusion efficiency was as high as 50% when determined
by CD2 expression (Fig. 1). We carefully examined the
fusion DC-T cells under microscopy, but did not find any
clustered cells. Therefore, higher antigenic load to DC
could be achieved by fusion than by in vitro viral infection
that might result in the induction of higher proliferative
response of CD8 T cells, although it remains to reveal
that the fusion DC-T cells effectively differentiate CD8 T
cells to anti-ATL cytotoxic T cells. The effect of antigenic
stimulation to DCs was also observed by the experiment
using 8Az, which is a representative metabolic antago-
nist. The 8Az can up-regulate the expression of intracy-
toplasmic Ags and is especially useful for Ags with low
immunogenicity. In fact, the 8Az was effective in up-
regulating the expression of HTLV-I Ag on the surface of
CD4 T cells (Fig. 6). However, 8Az did not largely affect
MHC and CD86 Ags expression on fusion DC-T cells (not
shown). Therefore, the higher expression of HTLV-I Ag on
CD4 T cells could be associated with a higher CD8 T
cell proliferative response to fusion DC-T cells (Fig. 7).
Taken together, the fusion cells of DCs and HTLV-I-
infected T cells can be considered to be a useful inducer
of higher immune response by up-regulating APC-asso-
ciated and antigenic molecules.
The most important point in evaluating the clinical use
of fusion DC-T cells is the fear of inducing autoimmune
responses. In this article, this point was assessed by
using fusion between DCs and DCs, HTLV-I-infected T
cells and HTLV-I-infected T cells, and DCs and autolo-
gous PHA-blasts. Neither of these fusions induced a
vigorous proliferation of autologous T cells as has been
reported by Kugler (Kugler et al., 2000). Here, we have
ruled out the possibility that fusion DC-T cells induce
autoimmune responses, although we have to be careful
in reaching any definite conclusion, and more detailed
analyses including secondary immune responses are
required.
Taken together, these results show that mature DCs-
HTLV-I-infected CD4 T cells fusion might be able to
provide a potent immunotherapeutic tool against ATL.
MATERIALS AND METHODS
Cell preparation
Peripheral blood mononuclear cells (PBMCs) were
obtained from more than 10 uninfected healthy donors
and monocyte-derived DCs were differentiated from
plastic-adherent monocytes (Makino et al., 1997, 1999). In
brief, CD3 T cells were removed from either freshly
isolated or cryopreserved PBMCs using immunomag-
netic beads coated with anti-CD3 monoclonal antibody
(mAb) (Dynabeads 450, Dynal, Oslo, Norway), and sub-
sequently plastic-adherent monocytes were obtained by
washing nonadherent cells extensively. The monocytes
were cultured in 10% fetal calf serum for 6 days in the
presence of 50 ng of recombinant (r) GM-CSF (Pepro
Tech EC Ltd., London, U.K.) and 10 ng of rIL-4 (Pepro
Tech EC Ltd.) per milliliter. rGM-CSF and rIL-4 were
supplied every 2 days as described previously (Makino
et al., 1997, 1999).
Maturation of the DCs was accomplished by treating
the immature DCs with 10 ng lipopolysaccharide (LPS,
Escherichia coli 0111:B4, Difco Laboratories, Detroit, MI)
or 10 ng tumor necrosis factor- (TNF-, Boehringer
Mannheim GmbH, Germany) per milliliter. The antigen-
presenting function of the mature DCs was assessed
after treatment with 50 g mitomycin-C per milliliter to
block the proliferation of remnant T cells (if any) in the DC
population.
Preparation of cell-free HTLV-I virions and infection of
T cells with HTLV-I
HTLV-I-producing cell line MT-2, a generous gift from
Dr. Y. Tanaka (Ryukyuu Univ. School Medicine, Okinawa,
Japan), was used as a viral source. Cell-free HTLV-I
virions were prepared by sonicating 5  106 MT-2 cells
per milliliter for 50 s as described before (Makino et al.,
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2000). Virions released into the supernatant from the
sonicated MT-2 cells were collected and used as a
cell-free viral source. As described previously that the
cell-free HTLV-I infected to both CD4 T cells and imma-
ture DCs (Makino et al., 1999), the 50% cell culture
infective dose (CCID50) of cell-free HTLV-I was deter-
mined using CD4 T cells as target cells in the presence
of 2 g/ml PHA (Difco) and 100 U/ml of rIL-2 (TGP-3,
Takeda Chemical Industries, Osaka, Japan). The infec-
tion of HTLV-I to CD4 T cells was determined using
PCR. In brief, DNA was extracted from CD4 T cells
using a DNA extractor kit (Wako Pure Chemical Indus-
tries, Ltd., Osaka, Japan) and was amplified by PCR using
a primer pair corresponding to nucleotides 1729 to 1750
and 1942 to 1964 of HTLV-Igag region (Makino et al.,
1999). Twenty CCID50 of HTLV-I virions were infected to
the immature DCs. HTLV-I infection was assessed by the
measurement of HTLV-Igag Ags on the surface using
FACScan (Becton–Dickinson Immunocytometry System,
San Jose, CA) as described previously (Makino et al.,
1999).
HTLV-I-infected CD4 T cells were prepared by infect-
ing HTLV-I to CD4 T cells donated from healthy donors
in vitro. The CD4 T cells were cocultured with mitomy-
cin-C-treated MT-2 cells in the presence of PHA and rIL-2
and also in the presence or absence of 2.5 g/ml 8Az
(Sigma Chemical Co., St. Louis, MO) for 7 days. At day 7
of culture, live-activated T cells were obtained using 30
and 55% gradient Percoll solutions (Pharmacia, Piscat-
away, NJ) and were maintained in the presence of 2
g/ml PHA and 100 U/ml rIL-2 to establish an HTLV-I-
infected T cell line (Takamoto et al., 1997).
Preparation of fusion of mature DCs and HTLV-I-
infected CD4 T cells (fusion DC-T cells)
The monocyte-derived mature DCs were fused with
HTLV-I-infected CD4 T cells in the presence of polyeth-
ylene glycol (PEG, MW 4000, Merck, Darmstadt, Ger-
many) as reported by Lespagnard et al. (1998). In brief,
the mature DCs and HTLV-I-infected CD4 T cells were
mixed and washed with prewarmed Dulbecco’s PBS ()
(Nissui Pharmaceutical Co., Tokyo, Japan). These cells
were treated with 50% PEG solution for 45 s at room
temperature and for another 45 s at 37°C in a water bath.
These cells were extensively washed to remove PEG,
resuspended in RPMI 1640 medium containing 10% FCS,
50 ng of rGM-CSF, and 10 ng of rIL-4 per milliliter, and
cultured for another 24 h at 37°C.
Analysis of cell surface Ags
The expression of cell-surface Ags on the DCs, T cells,
and fusion DC-T cells was determined using FACScan.
Dead cells were eliminated from the analysis by staining
with propidium iodide (Sigma Chemical Co.) and only live
cells (1  104) were gated for analysis. We used fluores-
cein isothiocyanate (FITC)-conjugated mAb against HLA-
ABC (G46–2.6) and HLA-DR (L243, Becton–Dickinson),
CD40 (5C3, PharMingen, San Diego, CA) and CD80 (BB1,
PharMingen), phycoerythrin-labeled mAb against CD54
(HA58; Becton Dickinson) and CD86 (IT2.2, PharMingen),
and purified murine mAb to HTLV-I gag Ag (GIN 14)
(generously given to us by Dr. Y. Tanaka), which was
followed by FITC-labeled Goat F(ab)2 anti-mouse Igs
(Tago-Immunologicals, Camarillo, CA), for the analyses
of cell-surface antigens. The optimal concentrations of
mAbs were determined in advance.
Assessment of antigen-presenting function of
HTLV-I-infected DCs and fusion DC-T cells
The APC function of DCs and fusion cells was as-
sessed using mixed autologous DCs and T cells reac-
tion. The virus-infected HTLV-I-infected DCs and fusion
DC-T cells were used as a stimulator, and unseparated T
cells, purified CD4 T cells, and CD8 T cells were used
as responder populations. Proliferation of stimulator
cells was confirmed to be completely blocked by mito-
mycin-C. The DCs and fusion DC-T cells were exten-
sively washed and plated to give a stimulator responder
ratio of 1:20 or 1:10. The responder T cells were purified
as follows: MHC class II cells were removed from
cryopreserved PBMCs using immunomagnetic beads
coated with anti-MHC class II mAb (Dynabeads 450,
Dynal) and further treated with beads coated with either
anti-CD4 mAb or anti-CD8 mAb to select T cell subsets
negatively. The purity of CD4 T cells and CD8 T cells
was more than 98%. Both stimulator and responder cells
(1  105 per well) were plated in 96-well round-bottom
tissue culture plates. The cell proliferation during the last
10 h of a 4-day culture in the presence of 4% heat-
inactivated human serum (a generous gift from Ka-
goshima Red Cross Blood Center) was quantified by
incubating the cells with 1 Ci/well [3H]thymidine. The
results are expressed as the mean value in cpm ob-
tained from triplicate cultures.
Statistical analysis
Student’s t test was applied to reveal statistically sig-
nificant differences.
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